(Q38614176)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

0 references

Heart failure with preserved ejection fraction

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Michele Senni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Emilia D'Elia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Muthiah Vaduganathan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Antonello Gavazzi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Javed Butler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

23 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Heart Failure

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

1231-1239

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

21 January 2018

1 reference

Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry

21 January 2018

1 reference

In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry

21 January 2018

1 reference

Phenotypic spectrum of heart failure with preserved ejection fraction

21 January 2018

1 reference

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes

21 January 2018

1 reference

Developing therapies for heart failure with preserved ejection fraction: current state and future directions

21 January 2018

1 reference

Markers of fibrosis, inflammation, and remodeling pathways in heart failure.

21 January 2018

1 reference

Biomarkers of heart failure with normal ejection fraction: a systematic review

21 January 2018

1 reference

State of the Art: Newer biomarkers in heart failure

21 January 2018

1 reference

Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction

21 January 2018

1 reference

Ventricular remodeling in heart failure with preserved ejection fraction

21 January 2018

1 reference

Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.

21 January 2018

1 reference

Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction

21 January 2018

1 reference

Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure

21 January 2018

1 reference

The crosstalk between the kidney and the central nervous system: the role of renal nerves in blood pressure regulation

21 January 2018

1 reference

Interactions between the sympathetic nervous system and the RAAS in heart failure

21 January 2018

1 reference

Neurohumoral pathways in heart failure with preserved systolic function

21 January 2018

1 reference

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

Treatment of heart failure with normal ejection fraction: an inconvenient truth!

21 January 2018

1 reference

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

21 January 2018

1 reference

Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

21 January 2018

1 reference

Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.

21 January 2018

1 reference

Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin

21 January 2018

1 reference

Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.

21 January 2018

1 reference

Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure

21 January 2018

1 reference

ST2: a novel biomarker for heart failure

21 January 2018

1 reference

Galectins: structure, function and therapeutic potential

21 January 2018

1 reference

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

21 January 2018

1 reference

Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.

21 January 2018

1 reference

Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?

21 January 2018

1 reference

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

21 January 2018

1 reference

Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).

21 January 2018

1 reference

Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials

21 January 2018

1 reference

ST2: a novel remodeling biomarker in acute and chronic heart failure

21 January 2018

1 reference

Elevated soluble ST2 and depression increased the risk of all-cause mortality and hospitalization in patients with heart failure.

21 January 2018

1 reference

Novel biomarkers in heart failure with preserved ejection fraction

21 January 2018

1 reference

Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction.

21 January 2018

1 reference

Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction

21 January 2018

1 reference

Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients

21 January 2018

1 reference

Induction of cardiac fibrosis by aldosterone

21 January 2018

1 reference

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment

21 January 2018

1 reference

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

21 January 2018

1 reference

Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology

21 January 2018

1 reference

Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

21 January 2018

1 reference

Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial

21 January 2018

1 reference

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

21 January 2018

1 reference

Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease

21 January 2018

1 reference

METformin in DIastolic Dysfunction of MEtabolic syndrome (MET-DIME) trial: rationale and study design : MET-DIME trial.

21 January 2018

1 reference

Prognostic impact of statin use in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction

21 January 2018

1 reference

Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study

21 January 2018

1 reference

Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population

21 January 2018

1 reference

Serum cardiac troponin T and plasma brain natriuretic peptide in patients with cardiac decompensation

21 January 2018

1 reference

Heart failure preserved ejection fraction with coronary artery disease: time for a new classification?

21 January 2018

1 reference

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure

21 January 2018

1 reference

Prognosis of new-onset heart failure outpatients and collagen biomarkers

21 January 2018

1 reference

Older Adults, "Malignant" Left Ventricular Hypertrophy, and Associated Cardiac-Specific Biomarker Phenotypes to Identify the Differential Risk of New-Onset Reduced Versus Preserved Ejection Fraction Heart Failure: CHS (Cardiovascular Health Study).

21 January 2018

1 reference

Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity

21 January 2018

1 reference

Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts

21 January 2018

1 reference

Ranolazine in heart failure with preserved left ventricular ejection fraction and microvascular dysfunction: case report and literature review

21 January 2018

1 reference

Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.

21 January 2018

1 reference

Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.

21 January 2018

1 reference

The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure

21 January 2018

1 reference

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

21 January 2018

1 reference

Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients

21 January 2018

1 reference

MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure

21 January 2018

1 reference

Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction

21 January 2018

1 reference

Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application

21 January 2018

1 reference

Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction

21 January 2018

1 reference

Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction

21 January 2018

1 reference

Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction

21 January 2018

1 reference

Diastolic Stiffness of the Failing Diabetic Heart

21 January 2018

1 reference

Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart

21 January 2018

1 reference

7 January 2021

Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle

1 reference

7 January 2021

The many faces of heart failure with preserved ejection fraction

1 reference

7 January 2021

Renin-Angiotensin System Blockade and Worsening Renal Function in Heart Failure

1 reference

7 January 2021

The perindopril in elderly people with chronic heart failure (PEP-CHF) study

1 reference

7 January 2021

Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?

1 reference

7 January 2021

CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF

1 reference

7 January 2021

Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure

1 reference

7 January 2021

Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. -Comparison between preserved and reduced ejection fraction heart failure.-.

1 reference

7 January 2021

Anti-inflammatory effects of simvastatin in patients with chronic heart failure

1 reference

7 January 2021

Implications of coronary artery disease in heart failure with preserved ejection fraction

1 reference

7 January 2021

Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification

1 reference

7 January 2021

Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers

1 reference

7 January 2021

Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina

1 reference

7 January 2021

HFpEF vs. HFrEF: can microRNAs advance the diagnosis?

1 reference

7 January 2021

Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort

1 reference

7 January 2021

Identifiers

DOI

10.1002/EJHF.430

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26493383%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference